These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17715379)

  • 1. Airway inflammation in COPD: friend or foe?
    Brusasco V; Crimi E; Pellegrino R
    Am J Respir Crit Care Med; 2007 Sep; 176(5):425-6. PubMed ID: 17715379
    [No Abstract]   [Full Text] [Related]  

  • 2. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation.
    Birrell MA; Wong S; Hele DJ; McCluskie K; Hardaker E; Belvisi MG
    Am J Respir Crit Care Med; 2005 Jul; 172(1):74-84. PubMed ID: 15805185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD.
    Fox JC; Fitzgerald MF
    Curr Opin Pharmacol; 2009 Jun; 9(3):231-42. PubMed ID: 19356979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of the distal airway in COPD].
    Cosío BG; Rodríguez Rosado J
    Arch Bronconeumol; 2011 Apr; 47 Suppl 2():32-7. PubMed ID: 21640283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role?
    Trevethick M; Clarke N; Strawbridge M; Yeadon M
    Curr Opin Pharmacol; 2009 Jun; 9(3):250-5. PubMed ID: 19286423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future therapies for airway mucus hypersecretion.
    Barnes PJ
    Novartis Found Symp; 2002; 248():237-49; discussion 249-53, 277-82. PubMed ID: 12568498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD.
    Morjaria JB; Malerba M; Polosa R
    Drug Discov Today; 2010 May; 15(9-10):396-405. PubMed ID: 20223295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of airway mucus hypersecretion.
    Rogers DF; Barnes PJ
    Ann Med; 2006; 38(2):116-25. PubMed ID: 16581697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation: friend or foe of muscle remodelling in COPD?
    Langen RC; Schols AM
    Eur Respir J; 2007 Oct; 30(4):605-7. PubMed ID: 17906080
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B
    Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs offer a lifeline for COPD and other respiratory diseases. Mucus-blocking medications could save countless lives.
    Duke Med Health News; 2013 Feb; 19(2):3. PubMed ID: 23495419
    [No Abstract]   [Full Text] [Related]  

  • 13. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease.
    Qiu S; Zhong X
    Ther Adv Respir Dis; 2017 Mar; 11(3):147-155. PubMed ID: 28030992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development.
    Fitzgerald MF; Fox JC
    Drug Discov Today; 2007 Jun; 12(11-12):479-86. PubMed ID: 17532533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?
    Zhang WH; Zhang Y; Cui YY; Rong WF; Cambier C; Devillier P; Bureau F; Advenier C; Gustin P
    Fundam Clin Pharmacol; 2012 Feb; 26(1):118-34. PubMed ID: 22044554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease.
    Donnelly LE; Barnes PJ
    Trends Pharmacol Sci; 2006 Oct; 27(10):546-53. PubMed ID: 16911834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of anti-inflammatory treatment with benacort in exacerbations of chronic obstructive lung disease].
    Kolesnikov VV; Korol'chuk IS
    Ter Arkh; 2003; 75(1):55-8. PubMed ID: 12652959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Statins in COPD--theoretical reflections].
    Hannink JD; Heijdra YF
    Ned Tijdschr Geneeskd; 2010; 154():A2196. PubMed ID: 20977805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives for cytokine antagonist therapy in COPD.
    de Boer WI
    Drug Discov Today; 2005 Jan; 10(2):93-106. PubMed ID: 15718158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathobiologic mechanisms of chronic obstructive pulmonary disease.
    Tam A; Sin DD
    Med Clin North Am; 2012 Jul; 96(4):681-98. PubMed ID: 22793938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.